|
|
|
|
|
Pramipexole
drug data and news
Pramipexole drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Pramipexole | ||
| Brand Names/Synonyms | Furfuryl Acetate; Mirapex; PRAMIPEXOLE HYDROCHLORIDE; Pramipexol; Pramipexol [Spanish]; Pramipexole; Pramipexole 2hcl Monohydrate; Pramipexole [Usan:Inn]; Pramipexolum [Latin]; SUD919CL2Y | ||
| Indication | For the treatment of signs and symptoms of idiopathic Parkinson's disease | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Pramipexole is a nonergot dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown. The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. This conclusion is supported by electrophysiologic studies in animals that have demonstrated that Pramipexole influences striatal neuronal firing rates via activation of dopamine receptors in the striatum and the substantia nigra, the site of neurons that send projections to the striatum. | ||
| Mechanism Of Action | The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum. | ||
| Pramipexole News (When available) |
Junior Jackpot: Teen Gambling On the Rise 16 May 2006 International Approvals: Sifrol/Mirapexin and Truvada Apr 24, 2006 What Illness Can We Think Up Next? ; MEDICAL NOTES May 9, 2006 Parkinson Disease Guidelines Aid Diagnosis, Management May 9, 2006 Boehringer Ingelheim's Sifrol/ Mirapexin treats restless legs ... May 8, 2006 Boehringer Ingelheim's Sifrol/ Mirapexin treats restless legs ... May 4, 2006 Researchers strive for clues to ALS Apr 20, 2006 | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Free Radical Scavengers; Antiparkinson Agents; Antidyskinetics; Antioxidants;; ATC:N04BC05 | ||
| Absorption | Not Available | ||
| Interactions |
-->Interactions for Pramipexole: Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). Pramipexole did not alter the extent of absorption (AUC) or the elimination of carbidopa/ levodopa, although it caused an increase in levodopa Cmax by about 40% and a decrease in Tmax from 2.5 to 0. 5 hours. Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro. Pramipexole does not inhibit CYP enzymes CYPIA2, CYP2C9, CYP2CI9, CYP2EI, and CYP3A4. Inhibition of CYP2D6 was observed with an apparent Ki of 30 uM, indicating that pramipexole will not inhibit CYP enzymes at plasma concentrations observed following the highest recommended clinical dose (1.5 mg tid). Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. Drug/ Laboratory Test Interactions There are no known interactions between MIRAPEX and laboratory tests. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | N'-propyl-4,5,6,7-tetrahydrobenzothiazole-2,6-diamine | ||
| Chemical Formula | C10H17N3S | ||
| Molecular Weight | 211.324 g/mol | ||
| Smiles String | CCCNC1CCC2=C(C1)SC(=N2)N | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | Not Available | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 8 hours | ||
| Protein Binding [%] | 15% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Pramipexole.html http://www.rxlist.com/cgi/generic2/prampex.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00156 | ||
| CAS Registry Number | 104632-26-0 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:196318 | ||
| PharmGKB ID | PA451085 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2241594 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |